A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Back to Search
Print
Bookmark Trial

NCT01254656

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Darlinghurst, New South Wales, 2010, Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
HIV-1
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must complete of 96 weeks of treatment with lersivirine (or comparator where required by local regulation) in one of the parent protocols (A5271015 or A5271022).

- Patients must have had a viral load less than 50 copies/mL at Week 84 of the parent protocol.

- For women who can have children, a negative urine pregnancy test at the Day 1 visit.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with any Grade 4 Division of AIDS toxicity (except for lipids and
asymptomatic glucose elevations will not be included in this trial.


- Patients being treated with another investigational product or in another clinical
trial, except the lersivirine parent protocols will not be included in this trial.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

ClinicalTrial[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

HIV-1Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1
NCT00795444
  1. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIV-1Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
NCT01345630
  1. Birmingham, Alabama
  2. Hobson City, Alabama
  3. Hayward, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. Newport Beach, California
  7. Palm Springs, California
  8. Sacramento, California
  9. Sacramento, California
  10. Sacramento, California
  11. San Francisco, California
  12. San Francisco, California
  13. San Francisco, California
  14. Santa Clara, California
  15. Union City, California
  16. Aurora, Colorado
  17. Denver, Colorado
  18. New Haven, Connecticut
  19. New Haven, Connecticut
  20. Norwalk, Connecticut
  21. Washington, District of Columbia
  22. Washington, District of Columbia
  23. Fort Lauderdale, Florida
  24. Fort Lauderdale, Florida
  25. Miami Beach, Florida
  26. Miami, Florida
  27. Miami, Florida
  28. Miami, Florida
  29. Miami, Florida
  30. Miami, Florida
  31. Miami, Florida
  32. Pensacola, Florida
  33. Tampa, Florida
  34. Tampa, Florida
  35. Tampa, Florida
  36. Tampa, Florida
  37. Tampa, Florida
  38. Wilton Manors, Florida
  39. Atlanta, Georgia
  40. Decatur, Georgia
  41. Decatur, Georgia
  42. Chicago, Illinois
  43. Chicago, Illinois
  44. Chicago, Illinois
  45. Iowa City, Iowa
  46. New Orleans, Louisiana
  47. New Orleans, Louisiana
  48. Springfield, Massachusetts
  49. Berkley, Michigan
  50. Detroit, Michigan
  51. Detroit, Michigan
  52. Detroit, Michigan
  53. East Lansing, Michigan
  54. East Lansing, Michigan
  55. Lansing, Michigan
  56. Minneapolis, Minnesota
  57. Kansas City, Missouri
  58. Omaha, Nebraska
  59. Neptune, New Jersey
  60. Neptune, New Jersey
  61. Neptune, New Jersey
  62. Newark, New Jersey
  63. Buffalo, New York
  64. New York, New York
  65. New York, New York
  66. New York, New York
  67. New York, New York
  68. Rochester, New York
  69. Valhalla, New York
  70. Charlotte, North Carolina
  71. Greenville, North Carolina
  72. Greenville, North Carolina
  73. Cincinnati, Ohio
  74. Toledo, Ohio
  75. Austin, Texas
  76. Dallas, Texas
  77. Dallas, Texas
  78. Dallas, Texas
  79. Dallas, Texas
  80. Houston, Texas
  81. Houston, Texas
  82. Houston, Texas
  83. Seattle, Washington
  84. Seattle, Washington
  85. Darlinghurst, New South Wales
  86. Darlinghurst, New South Wales
  87. Darlinghurst, New South Wales
  88. Surry Hills, New South Wales
  89. Brisbane, Queensland
  90. Carlton, Victoria
  91. Melbourne, Victoria
  92. Wien,
  93. Antwerpen,
  94. Brussels,
  95. Brussels,
  96. Bruxelles,
  97. Gent,
  98. Liege,
  99. Vancouver, British Columbia
  100. Ottawa, Ontario
  101. Ottawa, Ontario
  102. Toronto, Ontario
  103. Toronto, Ontario
  104. Montreal, Quebec
  105. Montreal, Quebec
  106. Hvidovre,
  107. Koebenhavn OE,
  108. Odense,
  109. Helsinki,
  110. Orleans, Cedex 02
  111. Paris, Cedex 12
  112. Paris, Cedex 18
  113. Bordeaux cedex,
  114. Creteil,
  115. Le Kremlin Bicetre,
  116. LYON Cedex 4,
  117. Montpellier,
  118. Nantes,
  119. Paris Cedex 10,
  120. Paris,
  121. Paris,
  122. Strasbourg Cedex,
  123. Tourcoing,
  124. Berlin,
  125. Berlin,
  126. Berlin,
  127. Bonn,
  128. Frankfurt am Main,
  129. Frankfurt am Main,
  130. Hamburg,
  131. Hamburg,
  132. Hamburg,
  133. Koeln,
  134. Muenchen,
  135. Muenchen,
  136. Budapest,
  137. Milano,
  138. Utrecht,
  139. Bydgoszcz,
  140. Warszawa,
  141. Wroclaw,
  142. Amadora,
  143. Lisboa,
  144. Lisboa,
  145. Porto,
  146. Bayamon,
  147. Ponce,
  148. Rio Piedras,
  149. Rio Piedras,
  150. San Juan,
  151. San Juan,
  152. L´hospitalet de Llobregat, Barcelona
  153. Alicante,
  154. Barcelona,
  155. Barcelona,
  156. Barcelona,
  157. Cordoba,
  158. Madrid,
  159. Madrid,
  160. Sevilla,
  161. Goteborg,
  162. Malmo,
  163. Stockholm,
  164. Stockholm,
  165. Basel,
  166. Bern,
  167. St. Gallen,
  168. Zurich,
  169. Birmingham,
  170. Brighton,
  171. Edinburgh,
  172. London,
  173. London,
  174. London,
  175. London,
  176. London,
  177. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIV-1Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection
NCT00850395
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIV-1Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
NCT00098293
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Beverly Hills, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. Los Angeles, California
  7. Newport Beach, California
  8. Oakland, California
  9. Sacramento, California
  10. San Francisco, California
  11. San Francisco, California
  12. Aurora, Colorado
  13. Jacksonville, Florida
  14. Miami Beach, Florida
  15. Miami, Florida
  16. Miami, Florida
  17. Orlando, Florida
  18. Sarasota, Florida
  19. Tampa, Florida
  20. Atlanta, Georgia
  21. Chicago, Illinois
  22. Indianapolis, Indiana
  23. Baltimore, Maryland
  24. Boston, Massachusetts
  25. Boston, Massachusetts
  26. Boston, Massachusetts
  27. Springfield, Massachusetts
  28. Omaha, Nebraska
  29. Albany, New York
  30. Brooklyn, New York
  31. Flushing, New York
  32. Manhasset, New York
  33. New York, New York
  34. Huntersville, North Carolina
  35. Cincinnati, Ohio
  36. Oklahoma City, Oklahoma
  37. Oklahoma City, Oklahoma
  38. Philadelphia, Pennsylvania
  39. Columbia, South Carolina
  40. Dallas, Texas
  41. Dallas, Texas
  42. Houston, Texas
  43. Houston, Texas
  44. Annandale, Virginia
  45. Puyallup, Washington
  46. Tacoma, Washington
  47. El Palomar, Provincia de Buenos Aires
  48. Neuquen, Provincia de Neuquen
  49. Buenos Aires,
  50. Ciudad de Buenos Aires,
  51. Ciudad de Buenos Aires,
  52. Ciudad de Buenos,
  53. Provincia de Buenos Aires,
  54. Provincia de Santa Fe,
  55. Burwood, New South Wales
  56. Darlinghurst, New South Wales
  57. Surrey Hills, New South Wales
  58. Wentworthville, New South Wales
  59. Herston, Queensland
  60. Miami, Queensland
  61. Melbourne, Victoria
  62. North Fitzroy, Victoria
  63. South Yarra, Victoria
  64. Brussels,
  65. Brussels,
  66. Gent,
  67. Leuven,
  68. Rio de Janeiro, RJ
  69. Calgary, Alberta
  70. Edmonton, Alberta
  71. Edmonton, Alberta
  72. Vancouver, British Columbia
  73. Vancouver, British Columbia
  74. Vancouver, British Columbia
  75. Vancouver, British Columbia
  76. Winnipeg, Manitoba
  77. Halifax, Nova Scotia
  78. Hamilton, Ontario
  79. Ottawa, Ontario
  80. Toronto, Ontario
  81. Toronto, Ontario
  82. Toronto, Ontario
  83. Montreal, Quebec
  84. Montreal, Quebec
  85. Montreal, Quebec
  86. Montreal, Quebec
  87. Montreal, Quebec
  88. Montreal, Quebec
  89. Sainte-Foy, Quebec
  90. Antella (FI),
  91. Brescia,
  92. Milano,
  93. Modena,
  94. Roma,
  95. Roma,
  96. Torino,
  97. Del. Tlalpan C.P., Mexico City
  98. Del. Tlalpan, C.P., Mexico D.F.
  99. Del. Tlalpan, C.P., Mexico D.F.
  100. Delegacion Tlalpan C. P, Mexico D.F.
  101. Amsterdam,
  102. Rotterdam,
  103. Utrecht,
  104. Bialystok,
  105. Bydgoszcz,
  106. Chorzow,
  107. Gdansk,
  108. Krakow,
  109. Szczecin,
  110. Warszawa,
  111. Ponce,
  112. Rio Piedras,
  113. San Juan,
  114. San Juan,
  115. Port Elizabeth, Eastern Cape
  116. Bloemfontein, Free State
  117. Johannesburg, Gauteng
  118. Pretoria, Gauteng
  119. Dundee, KwaZulu Natal
  120. Bloomfontein,
  121. Cape Town,
  122. Cape Town,
  123. Cape Town,
  124. Cape Town,
  125. Johannesburg,
  126. Pretoria North,
  127. Pretoria,
  128. Soweto, Johannesburg,
  129. Basel,
  130. Bern,
  131. Genève,
  132. Lugano,
  133. St. Gallen,
  134. Zürich,
  135. Zürich,
  136. Edinburgh, Loth
  137. Birmingham,
  138. Brighton,
  139. Edinburgh,
  140. London,
  141. London,
  142. London,
  143. London,
  144. Manchester,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
Official Title  ICMJE A Long Term Open-Label Extension Study Of Lersivirine For The Treatment Of HIV-1 Infection
Brief Summary This is a study to assess long-term safety and efficacy of lersivirine in patients who have completed 96 weeks of treatment with lersivirine in studies A5271015 and A5271022.
Detailed Description The trial was terminated prematurely on January 29, 2013, due to the decision of the sponsor to discontinue development of lersivirine. The decision to terminate the trial was not based on any safety or efficacy concerns.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV-1
Intervention  ICMJE
  • Drug: lersivirine
    Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
  • Drug: lersivirine
    Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
  • Drug: efavirenz
    Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
  • Drug: lersivirine
    Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
  • Drug: lersivirine
    Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
  • Drug: etravirine
    Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
Study Arms  ICMJE
  • Experimental: LRV 500mg
    Intervention: Drug: lersivirine
  • Experimental: LRV 750mg +TVD
    Intervention: Drug: lersivirine
  • Active Comparator: EFV
    Intervention: Drug: efavirenz
  • Experimental: LRV 750mg+ DRV/r + OBT
    Intervention: Drug: lersivirine
  • Experimental: LRV 1000mg +DRV/r + OBT
    Intervention: Drug: lersivirine
  • Active Comparator: ETR
    Intervention: Drug: etravirine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 27, 2014)		108
Original Estimated Enrollment  ICMJE
 (submitted: December 3, 2010)		165
Actual Study Completion Date  ICMJE April 2013
Actual Primary Completion Date April 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must complete of 96 weeks of treatment with lersivirine (or comparator where required by local regulation) in one of the parent protocols (A5271015 or A5271022).
  • Patients must have had a viral load less than 50 copies/mL at Week 84 of the parent protocol.
  • For women who can have children, a negative urine pregnancy test at the Day 1 visit.

Exclusion Criteria:

  • Patients with any Grade 4 Division of AIDS toxicity (except for lipids and asymptomatic glucose elevations will not be included in this trial.
  • Patients being treated with another investigational product or in another clinical trial, except the lersivirine parent protocols will not be included in this trial.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Brazil,   Canada,   Italy,   Mexico,   Poland,   South Africa,   Switzerland,   United Kingdom
Removed Location Countries Puerto Rico,   United States
 
Administrative Information
NCT Number  ICMJE NCT01254656
Other Study ID Numbers  ICMJE A5271037
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE ViiV Healthcare
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP